IgA Tarpeyo denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Tarpeyo as Duplicate Therapy — and Why That Denial Is Appealable

UnitedHealthcare may issue a duplicate-therapy denial for Tarpeyo (budesonide delayed-release capsules for IgA nephropathy) when it determines that another drug already on your claim covers the same therapeutic purpose. In IgA nephropathy, this most commonly occurs when a generic oral corticosteroid such as prednisone or prednisolone appears in your recent prescription history. UHC's automated claim-review system may flag both as corticosteroids and reject the newer agent as redundant.

This logic is flawed. Tarpeyo is an FDA-approved, targeted-release formulation specifically engineered to deliver active drug to Peyer's patches in the gut lining — the site where IgA immune complexes are thought to originate — and is then largely inactivated before systemic absorption. Generic systemic corticosteroids act through an entirely different distribution pattern and carry a distinct safety and tolerability profile. They are not clinically interchangeable, and treating them as duplicates misapplies the duplicate-therapy concept.

## Your Federal Appeal Rights

Even when UHC issues a final adverse benefit determination, federal law preserves robust appeal rights:

• ACA §2719 / DOL external-review rules: Non-grandfathered group and individual plans must offer at least one level of internal appeal followed by binding external review by an Independent Review Organization (IRO).
• ERISA §503: If your coverage is through an employer-sponsored plan, ERISA entitles you to a full-and-fair review of any denied claim.
• Timeline: You typically have 180 days from the denial notice to file an internal appeal, and up to approximately four months after exhausting internal remedies to request external review. Request an expedited review if your kidney function is declining rapidly — expedited decisions must be issued within 72 hours.

## Documentation to Gather Before You Appeal

1. Diagnosis confirmation — nephrology visit notes and pathology report confirming IgA nephropathy diagnosis (biopsy-proven when available). 2. Prior treatment history — dates, doses, and outcomes for every corticosteroid or immunosuppressive agent tried, including documented reasons for discontinuation or inadequate response. 3. Clinical distinction letter — a letter from your nephrologist explaining that Tarpeyo's targeted mechanism is clinically distinct from systemic corticosteroids and is not duplicative. 4. FDA prescribing label — the current FDA-approved label specifies the approved indication; confirm your prescriber's intended use matches it exactly. 5. UHC published coverage policy — obtain UHC's current medical/pharmacy coverage policy for Tarpeyo and note the specific criteria it lists.

## Criteria-Mapping Structure

Organize your appeal letter as a two-column table: copy each requirement from UHC's coverage policy in the left column, and supply the specific chart fact or document that satisfies it in the right column. Add a separate section quoting the FDA label's indication and your nephrologist's letter explaining the mechanistic distinction from systemic steroids. End with a direct statement that no true therapeutic duplicate exists for this drug's specific mechanism and indication.